Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA (tenapanor), a First-In-Class Treatment for IBS-C in Adults

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of IBSRELA (tenapanor) was presented at the 2024 Digestive Disease Week Conference (DDW), currently taking place in Washington, D.C. IBSRELA is a first-in-class treatment that is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.

“We are thrilled to share new data on the safety and efficacy of IBSRELA in adults with IBS-C at this year’s DDW Conference as we seek to continually elucidate its potential benefit in this patient population. These data provide additional information for both patients and prescribers as they consider IBSRELA as a potential new treatment option when symptoms of IBS-C persist despite current therapies,” said Laura Williams, MD MPH, chief medical officer of Ardelyx. “These analyses provide further evidence of the role IBSRELA could play, with its novel mechanism of action, in the treatment of IBS-C.”

Poster # Tu1658, entitled “Efficacy of Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): A Post Hoc Analysis of Patients with and Without Prior Use of Other IBS-C Prescription Medications from The Phase 3 T3MPO-1 and T3MPO-2 Studies,” reported results from a post hoc analysis of the T3MPO-1 and T3MPO-2 studies of tenapanor in adult patients with IBS-C to examine if there was a difference in efficacy between patients who had prior use of other IBS-C prescription medications and those without. A clinically meaningful response to tenapanor – defined as a complete spontaneous bowel movement response and an abdominal pain response in the same week for ≥6 of the first 12 treatment weeks – was observed among adults with IBS-C regardless of prior IBS-C prescription medication use.

Poster # Tu1663, entitled “Comparing the Efficacy of Tenapanor in Irritable Bowel Syndrome with Constipation in Hispanic vs Non-Hispanic Patients: A Posthoc Analysis of Patients in the Phase 3 T3MPO-1 and T3MPO-2 Studies,” reported results from a pooled analysis of the T3MPO-1 and
T3MPO-2 studies of tenapanor in adult patients with IBS-C to examine the relationship between the efficacy of tenapanor and patients of Hispanic ethnicity. Per the analysis, efficacy of tenapanor was comparable, or more pronounced, in Hispanic patients than in non-Hispanic patients.